Education
About Us
Working with TipRanks
Follow Us
Teladoc (TDOC)
NYSE:TDOC
Top Page
Teladoc
(NYSE:TDOC)
45Neutral
Positive Factors
Financial Performance
Projected free cash flow of $199 million is within management's guidance, reflecting healthy cash generation capabilities.
Program Expansion
Teladoc announced expansion of its Comprehensive Weight Care program which now includes a new relationship to provide lower cost, self-pay access to GLP-1 medicine.
Negative Factors
Growth Challenges
The softer revenue/EBITDA guidance will be the biggest focus point and will weigh on shares.
Teladoc (TDOC) vs. S&P 500 (SPY)
Market Cap
$1.55B
Dividend YieldN/A
Average Volume (3M)10.52M
Price to Earnings (P/E)―
Beta (1Y)1.62
Revenue Growth-1.26%
EPS Growth-338.56%
CountryUS
Employees5,600
SectorHealthcare
Sector Strength78
IndustryHealthcare Providers & Services
Share Statistics
EPS (TTM)-5.88
Shares Outstanding173,672,030
10 Day Avg. Volume10,093,955
30 Day Avg. Volume10,517,543
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.62
Price to Cash Flow (P/CF)4.60
P/FCF Ratio4.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.17Price Target Upside25.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Teladoc Business Overview & Revenue Model
Company DescriptionTeladoc Health, Inc. (TDOC) is a leading provider of virtual healthcare services, operating primarily in the telemedicine sector. The company offers a broad range of virtual care solutions, including telehealth consultations, mental health services, and expert medical services. Teladoc's platform connects patients with licensed healthcare professionals via video, phone, or app-based interactions, allowing for convenient and accessible medical care.
How the Company Makes MoneyTeladoc generates revenue primarily through a subscription-based model, where individuals or organizations pay for access to its virtual healthcare services. Key revenue streams include membership fees from health plans, employers, and individual users who subscribe to its telemedicine services. Additionally, the company earns income from fees charged per virtual visit, which are paid by health plans or directly by patients. Significant partnerships with healthcare providers, insurance companies, and employers enhance its market reach and contribute to its earnings. Teladoc also offers specialized services and second opinion consultations, which further diversify its revenue sources.
Teladoc Financial Statement Overview
Summary
Teladoc faces significant financial challenges with consistent net losses and high leverage. While there are strengths in cash flow generation, operational inefficiencies and competitive pressures in revenue growth present major hurdles. Improvements in profitability and debt management are crucial.Income Statement
Teladoc's income statement reveals significant challenges with profitability. The company has consistently reported negative net income and EBIT margins, indicating operational inefficiencies or high expenses. Gross profit margins reflect solid operational revenue, yet the inability to achieve net profitability and negative EBIT margins are concerning. Revenue growth has slowed, suggesting potential market saturation or competitive pressures.35
Negative
Balance Sheet
Teladoc's balance sheet shows moderate stability but is pressured by high debt levels. The debt-to-equity ratio remains high, indicating potential financial leverage risks. Stockholders' equity has decreased, which may affect future financing options. However, the company maintains a reasonable equity ratio, demonstrating some level of asset coverage by equity.45
Neutral
Cash Flow
The cash flow statement shows a mixed picture. Free cash flow has grown, which is positive, yet the operating cash flow relative to net income indicates inefficiencies in converting sales into cash. The free cash flow to net income ratio is positive, suggesting some capacity to generate cash despite ongoing losses.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.57B | 2.60B | 2.41B | 2.03B | 1.09B | Gross Profit |
| 1.82B | 1.84B | 1.66B | 1.38B | 703.13M | EBIT |
| -1.02B | -248.55M | 13.20B | -238.99M | -418.19M | EBITDA |
| -587.01M | 154.00M | -13.38B | -84.67M | -438.01M | Net Income Common Stockholders |
| -1.00B | -220.37M | -13.66B | -428.79M | -485.14M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.30B | 1.12B | 918.18M | 896.02M | 786.57M | Total Assets |
| 3.52B | 4.39B | 4.35B | 17.73B | 17.76B | Total Debt |
| 1.58B | 1.59B | 1.57B | 1.27B | 1.47B | Net Debt |
| 286.29M | 468.60M | 655.15M | 373.96M | 731.97M | Total Liabilities |
| 2.03B | 2.07B | 2.04B | 1.69B | 1.87B | Stockholders Equity |
| 1.49B | 2.33B | 2.31B | 16.05B | 15.88B |
| Cash Flow | Free Cash Flow | |||
| 282.89M | 193.67M | 16.53M | 130.06M | -79.55M | Operating Cash Flow |
| 293.68M | 350.02M | 189.29M | 193.99M | -53.51M | Investing Cash Flow |
| -124.05M | -156.35M | -167.74M | -72.98M | -590.98M | Financing Cash Flow |
| 8.31M | 10.85M | 6.50M | 40.95M | 859.14M |
Teladoc Technical Analysis
Negative
8.93
Price Trends
10.51
Negative
10.16
Negative
9.56
Negative
Market Momentum
-0.62
Positive
36.87
Neutral
16.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Negative. The current price of 8.93 is below the 20-day moving average (MA) of 11.06, below the 50-day MA of 10.51, and below the 200-day MA of 9.56, indicating a bearish trend. The MACD of -0.62 indicates Positive momentum. The RSI at 36.87 is Neutral, neither overbought nor oversold. The STOCH value of 16.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TDOC.
Teladoc Risk Analysis
Teladoc disclosed 56 risk factors in its most recent earnings report. Teladoc reported the most risks in the “Ability to Sell” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Teladoc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $11.34B | 60.35 | 21.24% | ― | 17.47% | 49.87% | |
53 Neutral | $4.42B | ― | -4584.47% | ― | 31.04% | 16.91% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
45 Neutral | $1.55B | ― | -52.46% | ― | -1.26% | -338.56% | |
44 Neutral | $22.44M | ― | -221.25% | ― | -59.08% | 18.99% | |
43 Neutral | $125.50M | ― | -54.13% | ― | -1.81% | 70.88% |
* Healthcare Sector Average
Performance Comparison
TDOC
Teladoc
9.00
-6.37
-41.44%
CARA
Cara Therapeutics
5.12
-5.44
-51.52%
GH
Guardant Health
42.63
23.99
128.70%
AMWL
American Well
8.14
-10.06
-55.27%
DOCS
Doximity
61.71
34.05
123.10%
Teladoc Earnings Call Summary
Earnings Call Date: Feb 26, 2025 | % Change Since: -18.74% | Next Earnings Date: Apr 23, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed view with significant growth in membership and international expansion, counterbalanced by revenue declines and challenges in BetterHelp and health plan channels. The company acknowledged headwinds but also highlighted strategic priorities and growth areas.Highlights
Membership and Visit Volume Growth
In 2024, Teladoc Health added over 4 million members in the U.S. and grew underlying visit volumes by 6%. Chronic Care management enrollment increased by 4%, and the company saw the strongest year of bookings since 2020 in their employer channel.
International Expansion Success
Teladoc's international business delivered mid-teens revenue growth in 2024. Notable expansions included partnerships in France for virtual psychiatry services and combining virtual services with proprietary devices in Canada.
BetterHelp Milestone
The BetterHelp segment reached a milestone of serving over 5 million people and maintained a high Net Promoter Score above 70. International revenue accounted for approximately 20% of BetterHelp's segment revenues.
Lowlights
Revenue Decrease
Full year 2024 consolidated revenue of $2.6 billion decreased 1% versus 2023. The BetterHelp segment revenue declined by 8% for the year.
BetterHelp Challenges
The BetterHelp business operated in a challenging environment, impacting financial performance in 2024. The average revenue per user declined sequentially due to international expansion with lower pricing.
Health Plan Channel Pressures
Challenges in the health plan channel due to macro factors and broader challenges. This impacted the sales and growth dynamics for Teladoc.
Chronic Care Client Loss
Teladoc was informed by a client of plans to transition a portion of their business during the second quarter, impacting Chronic Care enrollment growth.
Company Guidance
During the Teladoc Health Q4 2024 earnings call, the company provided guidance for 2025, highlighting several key metrics and strategic priorities. For the full year 2025, Teladoc expects consolidated revenue to be between $2.47 billion and $2.58 billion, with consolidated adjusted EBITDA projected in the range of $278 million to $319 million. The company anticipates free cash flow of $190 million to $220 million, representing a year-over-year increase of 12% to 30%. In terms of segment performance, the Integrated Care segment is expected to achieve flat to 3% revenue growth year-over-year, with an adjusted EBITDA margin of 14.8% plus or minus 50 basis points. Meanwhile, the BetterHelp segment is projected to see a revenue decline of 3.75% to 9.75% compared to 2024, with an adjusted EBITDA margin between 6.25% and 7.75%. Teladoc is focused on driving growth through increased member engagement, enhanced value per visit, productivity improvements, and international expansion. The company also plans to invest in its offerings and explore synergies across its mental health services, including BetterHelp's initiatives to expand payer coverage.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.